ArticlePloS one2014
CCR6 is a prognostic marker for overall survival in patients with colorectal cancer, and its overexpression enhances metastasis in vivo.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- CCL20-CCR6 axis in autoimmune disease and cancer progression: clinical and therapeutic implications.Cell communication and signaling : CCS · 2026Review
- Elevated CCL20 and IL-10 enhance 5-fluorouracil tolerance in colon cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome.Biomedicines · 2023Article
- A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma.BioMed research international · 2022Article
- Article
- Chemokine Receptor Antagonists: Role in Oncology.Current oncology reports · 2021Review
- Review
- Altered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2019Article
- Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization.International journal of molecular sciences · 2018Review
- Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer.Medicina (Kaunas, Lithuania) · 2018Review
- Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?Frontiers in endocrinology · 2018Review
- Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size.Gene · 2017Article
- Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages.Oncoimmunology · 2016Article
- TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.Nature communications · 2016Article
- Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors.Iranian journal of basic medical sciences · 2016Article
- Analysis of Chemokine Receptor Gene Expression in Esophageal Cancer Cells Compared with Breast Cancer with Insights into Metastasis.Iranian journal of public health · 2015Article
- The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages.Molecular cancer · 2015Article
- The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine receptor CCR6 has been recently shown to be associated with colorectal cancer (CRC) progression. However, the direct evidence for whether CCR6 in tumors is a prognostic marker for the survival of patients with CRC and whether it plays a critical role in CRC metastasis in vivo is lacking. Here we show that the levels of CCR6 were upregulated in CRC cell lines and primary CRC clinical samples. CCR6 upregulation was closely correlated with disease stages and the survival time of CRC patients. Knockdown of CCR6 inhibited the migration of CRC cells in vitro. Overexpression of CCR6 in CRC cells increased their proliferation, migration, and colony formation in vitro and promoted their metastatic potential in vivo. CCR6 activated Akt signaling, upregulated metastasis genes and downregulated metastasis suppressor genes. Selective targeting of CCR6 in tumors dramatically inhibited the growth of CRC in mice. Thus, the tumor expression of CCR6 plays a critical role in CRC metastasis, upregulated CCR6 predicts poor survival in CRC patients, and targeting CCR6 expression in tumors may be a potential therapeutic strategy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.